Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Syngene International Ltd Q4FY24; 6% rise in Profits
Categories
Drug Manufacturer
Neuland Laboratories Ltd Q4FY24; 20% fall in Profits
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. Financial Results: Neuland
Zim Laboratories Ltd Q1FY24; 96% fall in Profits
Zim Laboratories Limited is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these
Glenmark Life Sciences Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Glenmark Life Sciences Limited (GLS) Q3 FY23 Earnings Concall Q&A Highlights: [00:13:44] Tarang Agrawal of Old Bridge enquired about
Granules India Ltd (GRANULES) Q3 FY23 Earnings Concall Transcript
Granules India Ltd (NSE: GRANULES) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Irfan Raeen -- Investor Relation Advisor Krishna Prasad Chigurupati -- Chairman
Gland Pharma Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Gland Pharma Limited (GLAND) Q3 FY23 Earnings Concall Management Update: [00:06:08] GLAND said the insulin line is in the
Glenmark Life Sciences Limited Q2 FY23 Earnings Conference Call Insights
https://youtu.be/FHgUfHa30gw Key highlights from Glenmark Life Sciences Limited (GLS) Q2 FY23 Earnings Concall Management Update: [00:02:53] GLS said that the demand softness
Glenmark Life Sciences Limited (GLS) Q2 FY23 Earnings Concall Transcript
Glenmark Life Sciences Limited (NSE:GLS) Q2 FY23 Earnings Concall dated Oct. 21, 2022 Corporate Participants: Soumi Rao -- Head - Corporate Communications
Granules India Ltd (GRANULES) Q2 FY23 Earnings Concall Transcript
Granules India Ltd (NSE:GRANULES) Q2 FY23 Earnings Concall dated Oct. 20, 2022 Corporate participants: Irfan Raeen -- Investor Relation Dr. Krishna Prasad
Windlas Biotech Limited (WINDLAS) Q1 FY23 Earnings Concall Transcript
Windlas Biotech Limited (NSE:WINDLAS) Q1 FY23 Earnings Concall dated Aug. 05, 2022 Corporate Participants: Hitesh Windlass -- Managing Director Komal Gupta --